Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.
Widmer
N
N
Rumpold
H
H
Untergasser
G
G
Fayet
A
A
Buclin
T
T
Decosterd
L A
LA
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D020868:Gene Silencing; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D010879:Piperazines / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000493:pharmacokinetics*; D034741:RNA, Small Interfering / Q000494:pharmacology*
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D034741:RNA, Small Interfering; D000068877:Imatinib Mesylate